Oona Delpuech
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Journal: Cancer research
Published: March 03, 2023
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
Journal: Oncoimmunology
Published: June 27, 2022
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
Journal: NPJ precision oncology
Published: February 18, 2022
Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells.
Journal: Cancer research communications
Published: February 08, 2022
A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.
Journal: EMBO molecular medicine
Published: February 02, 2022
Heat inactivation of clinical COVID-19 samples on an industrial scale for low risk and efficient high-throughput qRT-PCR diagnostic testing.
Journal: Scientific reports
Published: July 29, 2021
Improving the efficiency and effectiveness of an industrial SARS-CoV-2 diagnostic facility.
Journal: Scientific reports
Published: July 29, 2021
A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce.
Journal: Scientific reports
Published: March 05, 2021
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
Journal: Journal of medicinal chemistry
Published: September 10, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
Journal: Molecular cancer therapeutics
Published: January 07, 2020
Last Updated: 09/26/2026